The information contained in this website is for general information purposes only. The information is provided by IXA and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of IXA . We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, IXA takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
CimCure, a spin-off of Amsterdam UMC and focusing on cancer immunotherapies for solid tumors, signed a strategic partnership agreement for in-licensing CimCure’s iBoost technology with Intravacc, a worldwide leading translational research and development vaccine organization with an extensive track record in developing viral and bacterial vaccines. The iBoost (immune boost) technology was developed at Amsterdam […]News
An annual survey held by the program directors of the Joint Master Entrepreneurship (UvA/ VU), Bram Kuijken and Enno Masurel, has found that 17.8% of alumni have founded their own company and 11.0% are currently working freelance. Additionally, the study found that 41.9% of alumni is employed by a startup (19.7%) or a scale-up (22.2%). […]News